This story mentions weight, weight loss, and/or GLP-1 drugs. In the last few years, GLP-1s, prescription weight loss ...

FDA ends GLP-1 drug shortage. Concerns over safety, counterfeit drugs, and high cost of brand-name versions persist; ...

Compounding pharmacies will have to stop producing copycats of tirzepatide, the active ingredient in the blockbuster weight ...

Compounded GLP-1s have given rise to a cottage industry offering cheaper weight loss medications to many Americans — but now ...

After years of weight loss drug shortages, the FDA is saying there’s now an adequate supply for most medications and they ...

As it gets harder to offer compounded GLP-1s, many telehealth companies are pivoting to hormone replacement therapy.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Recent research throws into question whether GLP-1 drugs increase the risk of certain types of thyroid cancer.

A product development expert explains how the swift rise of these anti-obesity medications is fueling new food trends.

Blockbuster GLP-1 medications are changing patient care, impacting surgery volumes and reshaping the financial landscape of the healthcare industry.

Stopping GLP-1 receptor agonists 14 days prior to total hip or knee arthroplasty may reduce several key risk factors ...

Why some health groups are banding together to push for a range of obesity-care options in workplace-sponsored insurance.